ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 39 of 94 for:    Recruiting, Not yet recruiting, Available Studies | "Anemia, Iron-Deficiency"

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02680756
Recruitment Status : Recruiting
First Posted : February 11, 2016
Last Update Posted : June 5, 2018
Sponsor:
Information provided by (Responsible Party):
Shield Therapeutics

Brief Summary:
The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent maintenance of haemoglobin in subjects with Inflammatory Bowel Disease (IBD).

Condition or disease Intervention/treatment Phase
Anemia, Iron-Deficiency Inflammatory Bowel Disease Crohn's Disease Drug: Ferric Maltol Drug: Ferric Carboxy Maltose Phase 3

Detailed Description:

A phase 3b, randomized, controlled, multicentre study with oral ferric maltol or intravenous iron (FCM), for the treatment of iron deficiency anaemia in subjects with inflammatory bowel disease.

Approximately 242 eligible subjects will be randomised (1:1) to receive one of the following treatments for the duration of the study treatment period (52 weeks):

  • Oral ferric maltol, 30 mg capsule bid.
  • Intravenous iron (ferric carboxy maltose) as per SPC

In the FCM arm IV iron treatment will be repeated if the subject is iron deficient at any of the study visits.

Subject participation in the study will consist of 3 periods:

  • Screening: Up to 14 days
  • Randomised Treatment: 52 weeks
  • Post-treatment safety follow-up: 14 days after study medication discontinuation

Primary efficacy and safety of ferric maltol and Intravenous iron (ferric carboxy maltose) will be evaluated after the first 12 weeks.

End of study evaluations will occur at Week 52 or premature discontinuation.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 242 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease
Actual Study Start Date : January 2016
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : March 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia Iron

Arm Intervention/treatment
Experimental: Oral ferric iron compound
30 mg capsules to be taken orally twice a day for 52 weeks
Drug: Ferric Maltol
Other Names:
  • Feraccru
  • Ferric Trimaltol
  • ST10
  • ST10-01

Active Comparator: Intravenous iron
Administered as per the local summary of product characteristics (SPC)
Drug: Ferric Carboxy Maltose



Primary Outcome Measures :
  1. Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (>12g/dL women, >13g/dL men) at Week 12 [ Time Frame: Baseline to Week 12 ]

Secondary Outcome Measures :
  1. Change in Hb concentration from baseline to Week 12 [ Time Frame: Baseline to Week 12 ]
  2. Change in Hb concentration from baseline to Week 12 in subjects with a baseline Hb <9.5 g/dL [ Time Frame: Baseline to Week 12 ]
  3. Proportion of subjects who experience a change from baseline in Hb concentration ≥1.0 g/dL at Week 12 [ Time Frame: Baseline to Week 12 ]
  4. Proportion of subjects with baseline Hb <9.5g/dL that achieve an increase in Hb concentration of ≥1 g/dL at Week 12 [ Time Frame: Baseline to Week 12 ]
  5. Proportion of subjects with Hb concentration within normal limits at Week 12 [ Time Frame: Baseline to Week 12 ]
  6. Proportion of subjects with baseline Hb concentration <9.5 g/dL that is within normal limits at Week 12 [ Time Frame: Baseline to Week 12 ]
  7. Long term efficacy endpoints i.e. proportion of subjects who are non-anaemic at 6 and 12 months; normalization of ferritin levels at 6 and 12 months [ Time Frame: Baseline to Month 6 and Month 12 ]
  8. Change in Hb concentration from baseline to Week 4 [ Time Frame: Baseline to Week 4 ]
  9. Change in Hb concentration from baseline to Week 4 in subjects with a baseline Hb <9.5 g/dL [ Time Frame: Baseline to Week 4 ]
  10. Proportion of subjects who experience a change from baseline in Hb concentration ≥2.0 g/dL at Week 12 [ Time Frame: Baseline to Week 12 ]
  11. Proportion of subjects with baseline Hb <9.5g/dL that achieve an increase in Hb concentration of ≥2 g/dL at Week 12 [ Time Frame: Baseline to Week 12 ]
  12. Proportion of subjects who experience a change from baseline in Hb concentration ≥1.0 g/dL at Week 4 [ Time Frame: Baseline to Week 4 ]
  13. Proportion of subjects with baseline Hb <9.5g/dL that achieve an increase in Hb concentration of ≥1 g/dL at Week 4 [ Time Frame: Baseline to Week 4 ]
  14. Proportion of subjects with Hb concentration within normal limits at Week 4 [ Time Frame: Baseline to Week 4 ]
  15. Proportion of subjects with baseline Hb concentration <9.5 g/dL that is within normal limits at Week 4 [ Time Frame: Baseline to Week 4 ]
  16. Proportion of subjects who experience a change from baseline in Hb concentration ≥2.0 g/dL at Week 4 [ Time Frame: Baseline to Week 4 ]
  17. Proportion of subjects with baseline Hb <9.5g/dL that achieve an increase in Hb concentration of ≥2 g/dL at Week 4 [ Time Frame: Baseline to Week 4 ]

Other Outcome Measures:
  1. Number of hospital or clinic visits for administration of IV iron [ Time Frame: Baseline to Week 52 ]
  2. Proportion of subjects who restart FCM during the study [ Time Frame: Baseline to Week 52 ]
  3. Other pharmacoeconomic endpoints [ Time Frame: Baseline to Week 52 ]
  4. Treatment-emergent Adverse Events (AEs) [ Time Frame: Baseline to Week 52 ]
  5. Treatment-emergent Serious Adverse Events (SAEs) [ Time Frame: Baseline to Week 52 ]
  6. Adverse Events leading to premature discontinuation of study drug [ Time Frame: Baseline to Week 52 ]
  7. Adherence to study medication [ Time Frame: Baseline to Week 52 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

All of the following criteria must be met to randomize a subject in the study:

  1. Subjects must be competent to understand the information given in the Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved informed consent form and must sign and date the informed consent prior to any study mandated procedure
  2. Subjects must be willing and able to comply with study requirements
  3. Age ≥ 18 years
  4. Subjects must have a confirmed diagnosis of IBD (endoscopic and/or biopsy)
  5. Subjects must be considered suitable for intravenous iron treatment by the Investigator
  6. Subjects must have iron deficiency anaemia defined by the following criteria:

    1. Hb 8.0 g/dL and ≤11.0 g/dL for women OR a Hb 8.0 g/dL and ≤12.0 g/dL for men
    2. AND Ferritin <30ng/ml OR Ferritin <100 ng/ml WITH Transferrin saturation (TSAT) <20%
  7. Female subjects of childbearing potential (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of contraception until they have completed the study and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), complete sexual abstinence, or a vasectomized partner. Oral contraceptive medications are allowed in this study. Female subjects who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or postmenopausal (defined as no menstrual period within 1 year of screening) are also allowed to participate.

A subject who meets any of the following criteria is not eligible for participation in the study.

  1. Subject with anaemia due to any cause other than iron deficiency, including, but not limited to:

    1. Untreated or untreatable severe malabsorption syndrome
    2. Immunosuppressant use. Immunosuppressants are permitted so long as there is no clinical evidence or suspicion of the immunosuppressant contributing to the subject's anaemia or affecting erythropoiesis.

    Variations to dosing are permitted at the discretion of the investigator so long as there is no clinical evidence or suspicion of the immunosuppressant contributing to the subject's anaemia or affecting erythropoiesis

  2. Subject who has received prior to screening:

    1. Within 8 weeks intramuscular or intravenous (IV) iron or administration of depot iron preparation
    2. Within 2 weeks a blood transfusion
    3. Oral iron supplementation, taken specifically to treat anaemia, within the previous 4 weeks (Over the Counter (OTC) multivitamins containing iron are permitted)
  3. Subjects with active inflammatory bowel disease as defined by a SCCAI score greater than 5 at Screening or a CDAI score greater than 300 in the Screening period (as assessed using the Screening haematocrit (HCT) and CDAI diary card completed by the subject for 7 days prior to planned randomization).
  4. Subjects with known hypersensitivity or allergy to either the active substance or excipients of ferric maltol capsules or ferric carboxymaltose solution for IV administration
  5. Subjects who have had serious adverse reactions to previous doses of ferric carboxymaltose or any other intravenous iron.
  6. Subjects with contraindication for treatment with iron preparations, e.g. hemochromatosis, chronic hemolytic disease, sideroblastic anaemia, thalassemia, or lead intoxication induced anaemia.
  7. Subjects with vitamin B12 or folic acid deficiency as determined by the central laboratory screening results. Subjects may start vitamin B12 or folate replacement and rescreen after at least 2 weeks.
  8. Subjects who are pregnant or breast feeding.
  9. Concomitant medical conditions with significant active bleeding likely to initiate or prolong anaemia.
  10. Participation in any other interventional clinical study within 30 days prior to screening.
  11. Subject with cardiovascular, liver, renal, haematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject or severely limit the lifespan of the subject (i.e. unlikely to complete the full duration of the study).
  12. Subject with significant neurologic or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately that might interfere with treatment compliance, study conduct or interpretation of the results (e.g., Alzheimer's disease, schizophrenia or other psychosis, active or current alcohol or drug abuse)
  13. Subject who is an inmate of a psychiatric ward, prison, or other state institution.
  14. Subject who is an Investigator or any other team member involved directly or indirectly in the conduct of the clinical study.
  15. Subjects with severe renal impairment: creatinine clearance <30 mL/min. (Applicable to US sites Only)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02680756


Contacts
Contact: Mark Sampson, MBChB msampson@shieldtherapeutics.com
Contact: Jackie Mitchell, PhD jmitchell@shieldtherapeutics.com

  Show 55 Study Locations
Sponsors and Collaborators
Shield Therapeutics
Investigators
Study Director: Mark Sampson, MBChB Shield Therapeutics

Responsible Party: Shield Therapeutics
ClinicalTrials.gov Identifier: NCT02680756     History of Changes
Other Study ID Numbers: ST10-01-304
First Posted: February 11, 2016    Key Record Dates
Last Update Posted: June 5, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Shield Therapeutics:
Iron Deficiency
Anaemia
Crohn's Disease
Deficiency Diseases
Inflammatory Bowel Diseases
Intestinal Diseases

Additional relevant MeSH terms:
Anemia, Iron-Deficiency
Anemia
Crohn Disease
Intestinal Diseases
Inflammatory Bowel Diseases
Hematologic Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Anemia, Hypochromic
Iron Metabolism Disorders
Metabolic Diseases
Iron
Ferric Compounds
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs
Hematinics